3239-KAN-Revyve_Box&Tube_LG-d2-FL
Kane Biotech and ProgenaCare Global Launch Newly Rebranded revyve™ Antimicrobial Wound Gel at Advanced Wound Care Fall Forum
02 nov. 2023 11h48 HE | Kane Biotech Inc.
WINNIPEG, Manitoba, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech”) in partnership with ProgenaCare Global LLP (“ProgenaCare”) today...
Kane Logo Cropped TransBG.png
Kane Biotech to Exhibit at Symposium on Advanced Wound Care Fall Forum
25 oct. 2023 07h45 HE | Kane Biotech Inc.
WINNIPEG, Manitoba, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces that it will be unveiling the new brand for its...
Kane Logo Cropped TransBG.png
Kane Biotech Announces Closing of Fully Subscribed Private Placement Offering and Amendments to its Credit Facility
12 sept. 2023 07h45 HE | Kane Biotech Inc.
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the...
Kane Logo Cropped TransBG.png
Kane Biotech Announces Second Quarter 2023 Financial Results
29 août 2023 16h29 HE | Kane Biotech Inc.
68% Increase in Product and Services Revenue; 74% Increase in Royalties Revenue WINNIPEG, Manitoba, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or...
Kane Logo Cropped TransBG.png
Kane Biotech to Release Second Quarter 2023 Financial Results on Aug 29, 2023 – Conference Call to Follow
22 août 2023 07h30 HE | Kane Biotech Inc.
WINNIPEG, Manitoba, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and...
Kane Logo Cropped TransBG.png
Kane Biotech Announces Private Placement Offering and Proposed Amendments to its Credit Facility
03 août 2023 07h45 HE | Kane Biotech Inc.
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”,...
Kane Logo Cropped TransBG.png
Kane Biotech Engages Research Capital to Conduct Strategic Review of STEM Animal Health
02 août 2023 07h30 HE | Kane Biotech Inc.
WINNIPEG, Manitoba, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) announced today that it has engaged Research Capital...
Kane Logo Cropped TransBG.png
Kane Biotech Announces Issuance of Restricted Share Units
23 juin 2023 17h30 HE | Kane Biotech Inc.
WINNIPEG, Manitoba, June 23, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF), (the “Company” or “Kane Biotech”), today announces that it has issued 9,703,809 restricted share...
Kane Logo Cropped TransBG.png
Kane Biotech Announces First Quarter 2023 Financial Results
25 mai 2023 16h05 HE | Kane Biotech Inc.
WINNIPEG, Manitoba, May 25, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and...
coactiv wound gel
Kane Biotech Announces FDA 510(k) Clearance for its coactiv+™ Antimicrobial Wound Gel
25 mai 2023 10h38 HE | Kane Biotech Inc.
WINNIPEG, Manitoba, May 25, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces that on May 24, 2023 it received 510(k) clearance of its...